Tom Hicks | October 27, 2026
You know that comforting little routine when you get sick? You see the doctor, explain what’s wrong, maybe get a prescription, and figure you’ll be back on your feet in a few days. We’ve grown so accustomed to antibiotics that we sometimes treat them like a guaranteed refund on whatever nasty little bastard has invaded our bodies.
Except the guarantee is getting harder to honor.
Today, the Centers for Disease Control and Prevention released its latest assessment of antimicrobial resistance. According to the CDC findings reported by ABC News, the 19 pathogens studied account for an estimated 9.7 million infections and 50,800 deaths annually in the United States.
That’s nearly 139 deaths a day.
More than 42,000 deaths are associated with infections commonly occurring in healthcare settings, according to The Washington Post’s examination of the new report.
Think about that the next time somebody tells you modern medicine can handle just about anything.
Modern medicine is remarkable. But some of the microscopic creatures we’re fighting have figured out how to survive the very drugs we invented to kill them.
And unlike the rest of us, they aren’t wasting time arguing on social media.
Laboratory professionals get results > Nellis Air Force Base > News
Laboratory testing helps identify resistant organisms and determine which medications may still work against them.
Fifty Thousand Deaths. And That’s Not the Whole Story.
The CDC’s 2026 threat assessment examines 19 pathogens, including bacteria and fungi. Four are classified as urgent threats, 13 as serious, and two as concerning. Another six organisms are on a watch list.
These aren’t science-fiction creatures waiting to escape from a secret laboratory. They’re already circulating in hospitals, nursing homes, communities, and other places where people live and receive care.
The previous comprehensive assessment, released in 2019, estimated 2.8 million resistant infections and more than 35,000 deaths annually. But the CDC warns against directly comparing those figures with today’s totals because the new report uses different data sources and calculation methods.
In fact, The Washington Post reports that the CDC attributes more than 80 percent of the apparent increase in infections to those methodological changes.
The estimates are based primarily on 2023 data. The total also includes Clostridioides difficile, or C. diff, which is associated with antibiotic use but isn’t ordinarily considered drug-resistant itself.
That’s worth explaining because frightening statistics don’t need help becoming frightening.
Even with those qualifications, the findings are deeply troubling.
Because the real danger isn’t confined to one particular infection. It’s what happens when the medications supporting much of modern medicine become less dependable.
The Hospital Is Supposed to Make You Better.
Here’s what bothers me most.
You can go into a hospital for a knee replacement, cancer treatment, a heart procedure, or something else entirely. The medical team may be perfectly capable of handling the original problem.
Then an infection enters the picture.
Maybe it’s pneumonia. Maybe it’s a bloodstream infection. Maybe it’s an infection around a surgical wound. Under ordinary circumstances, doctors have antibiotics or antifungal medications available to fight it.
But what happens when the organism responsible doesn’t respond?
The CDC explains that resistant infections can require longer hospital stays, additional treatment, and medications that may be more costly or toxic. And infectious disease specialists warn that resistance complicates chemotherapy, organ transplants, joint replacements, and other procedures that depend on effective infection prevention and treatment, as described in The Washington Post’s reporting.
Nach Einführung der Meldepflicht 30.000 Intensivbetten gezählt - Deutsche Apotheker Zeitung
Drug-resistant infections can complicate medical treatment and prolong hospital stays, particularly for patients already vulnerable to infection.
I’ve spent enough time around hospitals to appreciate what modern medicine can accomplish. I’ve also learned that there’s a big difference between getting through a medical procedure and getting safely through everything that follows it.
When you’re lying in a hospital bed, you shouldn’t have to wonder whether the infection-control system is keeping up with the germs.
Yet that’s exactly the challenge healthcare facilities are facing.
And the price isn’t limited to lives. The new report estimates that infections commonly associated with healthcare settings account for nearly $12 billion in annual healthcare costs, according to the CDC figures published by The Washington Post.
That’s an enormous amount of money spent dealing with organisms we would much rather have prevented from spreading in the first place.
More than 50,000 deaths a year. How much attention is this getting?
Subscribe to Off Script. I write about the politics, power struggles, and occasional magnificent bullshit that affect our lives.
It’s free, independent, and nobody gets a pass just because I happen to agree with them.
Meet the Fungus That Doesn’t Give a Damn About Our Medicine.
One of the report’s most alarming findings concerns Candida auris, a fungus that has become a particularly nasty problem in healthcare facilities.
It can survive on surfaces, spread among vulnerable patients, and cause severe infections. The CDC’s research on Candida auris documents its ability to spread in healthcare settings and develop resistance to antifungal medications.
Some strains resist multiple treatments, leaving doctors with fewer options. The CDC’s antifungal-resistance guidance notes that resistance to fluconazole is especially common, although resistance to the echinocandin drugs generally used as first-line treatment remains much less common.
According to The Washington Post’s account of the new report, Candida auris infections have increased roughly tenfold since 2019.
Tenfold.
That’s not a rounding error. It’s a warning.
Then there’s carbapenem-resistant Enterobacterales, or CRE. The name sounds like something you’d find on the back of a chemistry textbook, but the problem is straightforward: these bacteria can resist antibiotics doctors often reserve for serious infections.
Certain strains can also share resistance genes with other bacteria, potentially spreading the ability to defeat a medication. The new CDC estimates put CRE at 14,878 infections and 1,252 deaths among hospitalized patients in 2023, according to ABC News.
There’s also drug-resistant gonorrhea, which has developed resistance to nearly every antibiotic used against it over time. And drug-resistant meningococcal bacteria have been newly classified as a serious threat because they can cause life-threatening meningitis and bloodstream infections outside hospitals.
Those changes, including the addition of meningococcal bacteria, are detailed in the CDC report’s pathogen classifications.
These organisms don’t all behave the same way, and they don’t pose identical risks to every person. But together they demonstrate how many different directions the problem is moving.
We Helped Create This Mess.
Here’s where humanity gets to accept some responsibility.
Antibiotics transformed medicine. Diseases that once killed people routinely became treatable. Surgery became safer. Infections that might once have meant a death sentence could often be cleared with medication.
Then we started treating these drugs as though their effectiveness would last forever.
Antibiotics have been prescribed when they weren’t needed. Patients have sometimes pressured doctors for them even when dealing with viral illnesses, which antibiotics don’t treat. In some settings, antibiotics have been used more broadly or for longer than necessary.
The CDC’s guidance on antibiotic prescribing explains that unnecessary or incorrect use contributes to the resistance problem. And its patient guidance makes clear that antibiotics don’t work against viruses such as those responsible for colds and flu.
Outside human medicine, antimicrobial use in animals and agriculture adds another dimension. The CDC describes resistance as a problem spanning healthcare, veterinary medicine, agriculture, and the environment.
Every unnecessary exposure can create opportunities for resistant organisms to survive and spread. Resistance also occurs naturally, and even appropriate antibiotic use can select for it. This isn’t something we can solve by blaming every patient who ever asked for a prescription.
But responsible use matters.
If you need an antibiotic, take it as prescribed. If you don’t need one, taking it won’t help you recover faster. And if you’re unsure, ask the person treating you.
The CDC’s prevention strategy emphasizes preventing infections, improving antibiotic and antifungal use, and stopping resistant organisms from spreading.
None of that is glamorous.
Neither is washing your hands.
But glamorous isn’t the standard we should be using when lives are at stake.
The Drug Companies Have a Problem, Too.
Here’s another uncomfortable piece of this story.
Developing a new antibiotic can take years and cost an enormous amount of money. But unlike medications patients may take for decades, a new antibiotic might be used for only a short course of treatment.
And if it’s especially effective against dangerous resistant infections, doctors may deliberately reserve it for the patients who need it most.
That’s medically sensible. Financially, it’s a lousy business model.
We need new antibiotics available when older ones fail. Yet the very practices that help preserve those new drugs can limit the revenue companies earn from developing them.
One proposed answer is the bipartisan PASTEUR Act of 2026, Senate Bill 4875. Introduced June 23, it would establish a payment model designed to reward the development and availability of certain critically needed antimicrobial treatments rather than depending entirely on the number of prescriptions sold.
The bill’s legislative summary describes eligibility requirements and proposed contracts for qualifying drugs. As of the latest action I could verify, the Senate bill remained referred to the Health, Education, Labor, and Pensions Committee.
Supporters argue that the approach could encourage development while allowing doctors to preserve new drugs through careful use. Whether the proposed incentives would produce enough useful treatments at an acceptable cost is a legitimate question for Congress.
But doing nothing has a price, too. And some of that price is being paid by patients who run out of treatment options.
Antibiotika: Erstmals wieder über Pandemie-Niveau | APOTHEKE ADHOC
Antibiotic susceptibility testing helps laboratories determine which medications remain effective against a bacterial infection.
The Germs Aren’t Interested in Your Politics.
Remember the COVID years?
Of course you do. How could anybody forget?
We fought about masks, vaccines, school closings, public health officials, government authority, and whether the guy down the street knew more about infectious diseases than the people who’d spent their careers studying them.
Some of those arguments involved legitimate disagreements over policy, evidence, and individual rights. Others descended into conspiracy theories and political theater that made meaningful discussion almost impossible.
And while we were busy fighting, the microorganisms kept doing what microorganisms do.
They evolved. They spread. They found opportunities.
Antimicrobial resistance didn’t begin with COVID, and the pandemic didn’t create it. But CDC research on the pandemic’s impact documented a significant setback in controlling resistant infections.
In 2020, hospital-onset resistant infections and deaths involving seven pathogens increased by at least 15 percent compared with 2019. Hospitals faced staffing shortages, shortages of protective equipment, longer patient stays, and difficulties maintaining infection-control practices, according to the CDC’s July 2022 report.
The problem persisted beyond that first year. Updated CDC data showed that hospital-onset infections involving six resistant bacterial pathogens increased by a combined 20 percent during the pandemic period, peaking in 2021.
Now the CDC has put another serious warning on the table.
We can argue about how much money to spend, which programs work, how to hold pharmaceutical companies accountable, and how much authority public health agencies should have. Those arguments matter.
But the underlying biology doesn’t change depending on which party wins an election.
A resistant bacterium doesn’t check your voter registration before infecting you.
And a fungus doesn’t become susceptible to medication because somebody gave a particularly impressive speech.
There’s Some Good News. Let’s Not Ignore It.
The report isn’t entirely bleak.
Clostridioides difficile, commonly called C. diff, has been moved from the CDC’s urgent-threat category to its serious-threat category. The change reflects, in part, progress in infection prevention, particularly in healthcare settings, according to the CDC’s 2026 classifications.
The organism remains dangerous. But the change demonstrates that prevention efforts can make a difference.
And there’s more evidence that prevention works. CDC hospital surveillance data documented changes in healthcare-associated infections during the pandemic, including reductions in C. diff during periods when hospitals increased hand hygiene, protective equipment use, and environmental cleaning.
That’s important because I don’t want anybody walking away from this article thinking we’re helpless.
We’re not.
We have scientists studying these organisms, healthcare workers preventing their spread, laboratories detecting resistance, and researchers developing new treatments.
What we need is the willingness to keep supporting that work, even when it doesn’t produce a dramatic headline or a convenient political enemy.
One Question
Here’s something I’d genuinely like to hear readers argue about.
Should developing new antibiotics and preventing drug-resistant infections become a major national priority, even if that means additional federal spending?
Or should pharmaceutical companies and the healthcare industry be expected to solve the problem without more government involvement?
There are reasonable arguments about how to pay for the work and who should be accountable. What interests me is whether we can agree on the urgency before the next crisis forces the conversation.
Tell me what you think in the comments.
The Bullshit Detector 💩
Three fact-checks from outside today’s antimicrobial-resistance story.
1. THE VOTING MACHINES THAT SUPPOSEDLY SWITCH YOUR VOTE
CLAIM: Viral videos prove voting machines are deliberately changing voters’ selections during the 2026 midterms.
BULLSHIT: 💩💩💩💩 — 4/5
WHY: A video of a touchscreen problem isn’t, by itself, proof of deliberate election manipulation. Some viral claims recycle older footage or omit the circumstances of an incident. Problems should be reported and investigated, not automatically promoted as evidence of a nationwide conspiracy.
Fact-check: PolitiFact — October 24, 2026
2. THE PARIS BOUTIQUE OWNER WHO WASN’T
CLAIM: A French woman who supported welcoming asylum seekers was attacked by refugees who looted her Paris boutique.
BULLSHIT: 💩💩💩💩💩 — 5/5
WHY: The viral account attached an invented identity and political backstory to footage of a looting incident. The claim that the woman owned the business and had publicly supported asylum seekers wasn’t established.
Fact-check: Reuters — October 23, 2026
3. THE PODCASTER WHO DIED WITHOUT THE INCONVENIENCE OF BEING DEAD
CLAIM: Ethan Klein, host of the H3 Podcast, was found dead in October.
BULLSHIT: 💩💩💩💩💩 — 5/5
WHY: The death announcement was a hoax. A controversy involving the podcast is not evidence that its host died, no matter how enthusiastically the internet circulates the rumor.
Fact-check: Lead Stories — October 26, 2026
A Few Other Places Worth Your Time
If you’re tired of the endless political shouting, Chart Collision offers six songs, six clues, and a mystery Bonus Track. Lotus Purrspective provides daily household observations from a cat who considers herself the only qualified adult in the building. And Panic Room Sports brings smart coverage with attitude, particularly when coaches, officials, and owners deserve a little grief.
Over at Frank N. Krancke, a permanently irritated gentleman has been explaining why modern life keeps getting on his nerves. Tomorrow, Eve Next Door makes her debut, inviting everybody over for Wednesday coffee, a little neighborhood gossip, and whatever else she happens to notice.
And keep an eye out for Just Lucy, arriving Monday, November 2. She’s four-and-a-HALF, has a ten-year-old brother, and is beginning to suspect that grown-ups don’t understand nearly as much as they claim.
For the deeper political machinery, there’s Blind Spot. For wonderfully bizarre history, What the Hell?. And when you need an escape into the past, Rabbit Ears Classic TV and The Backlot Ghost revisit the television and movies that stuck with us.
The Conversation Doesn’t Have to End Here
We’ve also got a place to keep talking after the article ends. The Tom Hicks Media Discord is open for politics, health, music, sports, movies, cats, and whatever else catches somebody’s attention.
The Next Emergency Is Already Here.
I’m 70 years old. I’ve lived long enough to see diseases that once terrified people become treatable, surgeries that once seemed impossible become routine, and medications transform what it means to grow old.
I’d rather not watch us surrender those gains because we couldn’t get our priorities straight.
Fifty thousand deaths a year is not a hypothetical future disaster. It’s the CDC’s estimate of what’s happening already.
And here’s the part that stays with me.
For decades, we’ve relied on medicine to stay one step ahead of the germs.
The germs have never agreed to cooperate.
Maybe it’s time we stopped assuming they will.
#AntibioticResistance #Superbugs #CDC #PublicHealth #Healthcare #MedicalResearch #OffScript #THM